In clinical trials
Heart & blood
Selepressin
Evidence
Clinical trials
Class
Selective V1a receptor agonist
KEY TAKEAWAY
Selepressin is a synthetic vasopressin analog designed to act only on the V1a receptor. Selepressin is not FDA-approved. A large trial in septic shock was stopped in 2017 because it was unlikely to show benefit.
Written by the Veylo editorial team · Updated
November 2026
What it is
Selective V1a receptor agonist
Being studied for
Studied in septic shock
Key fact
Selepressin is not FDA-approved. A large trial in septic shock was stopped in 2017 because it was unlikely to show benefit.
Route
Intravenous infusion in trials
Evidence strength
Clinical trials
Selepressin is a synthetic vasopressin analog designed to act only on the V1a receptor.
It narrows blood vessels without the water-retaining effects of vasopressin, which was meant to help treat septic shock.
Selepressin is not FDA-approved. A large trial in septic shock was stopped in 2017 because it was unlikely to show benefit.
Studied in septic shock.
In trials, side effects were similar to standard care, but the drug did not improve outcomes.
Selepressin: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.